CAS: 1948229-21-7; 3-(5-Methylthiazol-2-yl)-5-(((R)-Tetrahydrofuran-3-yl)Oxy)-N-((R)-1-(2-(Trifluoromethyl)Pyrimidin-5-yl)Ethyl)Benzamide
- 英文名称3-(5-Methylthiazol-2-yl)-5-(((R)-Tetrahydrofuran-3-yl)Oxy)-N-((R)-1-(2-(Trifluoromethyl)Pyrimidin-5-yl)Ethyl)Benzamide
- 中文名称3-(5-甲基噻唑-2-基)-5-(((R)-四氢呋喃-3-基)氧基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)苯甲酰胺
- IUPAC名称3-(5-methylthiazol-2-yl)-5-(((R)-tetrahydrofuran-3-yl)oxy)-N-((R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide
- 其它别名Eliapixant [usan:Inn]; 3-(5-Methylthiazol-2-yl)-5-((3R)-Tetrahydrofuran-3-yl)Oxy-N-((1R)-1-(2-(Trifluoromethyl)Pyrimi
- CAS编号1948229-21-7
- MFCD编号:MFCD34470055
- FDA UNII编号:9GH7E6347B
- 分子式:C22H21F3N4O3S分子量:478.5
- 产品CID: 989562
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
2905399001-1,3-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:EP-4630405-A1
优先权日:2022-12-06
标题 :Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
专利号:WO-2024123815-A1
优先权日:2022-12-06
标 题:Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Morice A, Smith JA, McGarvey L, Birring SS, Parker SM, Turner A, Hummel T, Gashaw I, Fels L, Klein S, Francke K, Friedrich C. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo- controlled, crossover phase 2a study. Eur Respir J. 2021 Nov 18;58(5):2004240. doi: 10.1183/13993003.04240-2020.
2: Davenport AJ, Neagoe I, Bräuer N, Koch M, Rotgeri A, Nagel J, Laux-Biehlmann A, Machet F, Coelho AM, Boyce S, Carty N, Gemkow MJ, Hess SD, Zollner TM, Fischer OM. Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers. Sci Rep. 2021 Oct 6;11(1):19877. doi: 10.1038/s41598-021-99177-0.
3: Klein S, Gashaw I, Baumann S, Chang X, Hummel T, Thuß U, Friedrich C. First- in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics. Br J Clin Pharmacol. 2022 Oct;88(10):4552-4564. doi: 10.1111/bcp.15358. Epub 2022 May 22.
合成参考文献
参考文献:10.1183/13993003.04240-2020
摘要:Morice A, Smith JA, McGarvey L, Birring SS, Parker SM, Turner A, Hummel T, Gashaw I, Fels L, Klein S, Francke K, Friedrich C. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;58(5):2004240. doi: 10.1183/13993003.04240-2020.
📝 需求与反馈
尽可能描述清楚需求与问题信息
